SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS

Abstract

Enthesitis is inflammation at the site of attachment of tendon, ligament, or joint capsule to bone, a typical symptom of psoriatic arthritis (PsA). Heel enthesitis is of the greatest clinical significance. The activation of the interleukin 23/interleukin 17 (IL-23/IL-17) axis plays a pivotal role in the development of enthesitis. The latter can seriously limit the function of the musculoskeletal system and is incurable. If nonsteroidal anti-inflammatory drugs are ineffective, a biological agent should be immediately prescribed. The use of synthetic disease-modifying antirheumatic drugs for the treatment for enthesitis is not recommended due to their inefficacy. Despite the progress in the treatment of enteritis in PsA with tumor necrosis factor-α inhibitors, there is a need for the use of new drugs.The paper describes the clinical case of a patient with PsA who has been successfully treated for isolated destructive enthesitis of the heel with the IL-17А inhibitor secukinumab (Cosentyx).

Keywords

• psoriatic arthritis
• heel enthesitis
• secukinumab (cosentyx)